Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Eperimental Medicine and Surgery, University of Rome "Tor Vergata", Urology Unit, Policlinico Tor Vergata, Rome, Italy.
Neurourol Urodyn. 2019 Apr;38(4):1111-1119. doi: 10.1002/nau.23966. Epub 2019 Mar 8.
To evaluate the outcome of adjustable continence balloons in the treatment of stress urinary incontinence (SUI) after transurethral resection of the prostate (TURP).
In two tertiary centers, adjustable continence balloons were implanted in 29 patients with post-TURP SUI between 2007 and 2018. Endpoints of this retrospective multicenter study were patient-reported changes in pad count and complications. Dry was defined as no pad or one security pad.
Preoperative urinary incontinence was mild in 7 (24%), moderate in 12 (41%), and severe in 10 (35%) patients. The median follow-up duration was 21 (interquartile range [IQR], 11-43) months. Within 30 days postoperatively, a Clavien-Dindo grade less than or equal to II complication occurred in 24% of the patients. Reintervention rate was 24%. Six and 12 months after implantation, the International Prostate Symptom Score (IPSS) quality-of-life item improved significantly from 5 (IQR, 5-6) preoperatively to 3 (IQR, 1-4.5) and 1 (IQR, 0-3), respectively. At last visit (median 21 months after implantation), the outcome on continence had improved in 76% of the patients, including, 45% dry patients. After a median follow-up of 28 months (IQR, 13-63; N = 23), all but one patient reported improvement on the Patient Global Impression of Improvement (PGI-I) scale. In detail, 10 patients reported "very much better" condition compared with before the implantation, 10 patients "much better," two patients "a little better," and one patient "no change." Daily pad use decreased from three (IQR, 2-5) to one (IQR, 0-2) pads/day (P < 0.001).
This is hitherto, the first study reporting results of adjustable continence balloons in the treatment of post-TURP SUI. The therapy was found to be safe and efficient. The majority of our study population reported improvement on their condition and greater than or equal to 50% reduction in daily pad use.
评估可调性控尿球囊在经尿道前列腺电切术后(TURP)治疗压力性尿失禁(SUI)中的疗效。
在 2007 年至 2018 年间,在两家三级中心对 29 例 TURP 后 SUI 患者植入可调性控尿球囊。本回顾性多中心研究的终点是患者报告的垫计数变化和并发症。无垫或使用 1 片安全垫定义为干燥。
术前尿失禁轻度 7 例(24%),中度 12 例(41%),重度 10 例(35%)。中位随访时间为 21 个月(四分位距 [IQR],11-43)。术后 30 天内,24%的患者发生 Clavien-Dindo 分级≤Ⅱ级并发症。再干预率为 24%。植入后 6 个月和 12 个月时,国际前列腺症状评分(IPSS)生活质量项目分别从术前 5 分(IQR,5-6)显著改善至 3 分(IQR,1-4.5)和 1 分(IQR,0-3)。末次随访时(植入后中位时间 21 个月),76%的患者在控尿方面有改善,包括 45%的干燥患者。在中位随访 28 个月(IQR,13-63;N=23)后,除 1 例患者外,所有患者均报告改善患者整体印象改善(PGI-I)评分。具体而言,10 例患者报告与植入前相比,病情“明显好转”,10 例患者报告“好转很多”,2 例患者报告“略有好转”,1 例患者报告“无变化”。每日垫使用量从 3 片(IQR,2-5)减少至 1 片(IQR,0-2)(P<0.001)。
这是迄今为止第一项报告可调性控尿球囊治疗 TURP 后 SUI 结果的研究。该疗法被发现安全有效。我们的大多数研究对象报告病情改善,且每日垫使用量减少≥50%。